Camurus AB (publ) CAMRF
61.75 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
61.75 Day range 64.00
54.00 52-week range 71.00
- YTD
- -8.01%
- 1 year
- -10.31%
- Market cap
- 3.67B
- EPS (ttm)
- 1.21
- P/E ratio
- 51.03
- YTD return
- -8.01%
- 1-year return
- -10.31%
- Volume
- 200
- Avg volume
- 31
- Open
- 64.00
- Previous close
- 61.75
- Day's range
- 61.75 – 64.00
- 52-week range
- 54.00 – 71.00
- Earnings date
- Nov 5, 2026
2Y +4.75 (+8.33%)
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.4257.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.4257 | — | — | — |
| Jul 15, 2026 | Jun 30, 2026 | 0.3314 | 0.4175 | +0.09 | +25.98% |
| May 12, 2026 | Mar 31, 2026 | 0.3652 | 0.2525 | -0.11 | -30.86% |
| Feb 12, 2026 | Dec 31, 2025 | 0.2561 | 0.1807 | -0.08 | -29.44% |
| Nov 6, 2025 | Sep 30, 2025 | 0.3492 | 0.3463 | 0.00 | -0.83% |
| Jul 17, 2025 | Jun 30, 2025 | 0.3597 | 0.4292 | +0.07 | +19.32% |
News
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA 
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript 
Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback 
Camurus announces expansion of Lilly collaboration 
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript 
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript 
Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript 
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins 
US FDA declines to approve Camurus' rare hormone disorder drug 
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Your note
Sign in to keep a note on CAMRF — it syncs with the Stock Master app.